Endocrine treatment of transsexuals: assessment of cardiovascular risk factors

@article{Nakatsuka2010EndocrineTO,
  title={Endocrine treatment of transsexuals: assessment of cardiovascular risk factors},
  author={M. Nakatsuka},
  journal={Expert Review of Endocrinology \& Metabolism},
  year={2010},
  volume={5},
  pages={319 - 322}
}
  • M. Nakatsuka
  • Published 2010
  • Medicine
  • Expert Review of Endocrinology & Metabolism
Gender identity disorder (GID) is characterized by strong and persistent cross-gender identification and by persistent discomfort with one’s anatomical sex. Transsexualism is considered to be the extreme end of the spectrum of GID, which is characterized by a pursuit of sex reassignment surgery. The recent information on the prevalence of the transsexual end of the GID spectrum from The Netherlands is one in 11,900 males and one in 30,400 females [101], although biological mechanisms of GID are… Expand
1 Citations
Altered arterial stiffness in male‐to‐female transsexuals undergoing hormonal treatment

References

SHOWING 1-10 OF 17 REFERENCES
Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline.
Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.
Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.
The sudden and unexpected death of a female-to-male transsexual patient.
Association study of gender identity disorder and sex hormone-related genes
Testosterone decreases adiponectin levels in female to male transsexuals.
...
1
2
...